Tipifarnib Drug Asset Due Diligence Report 2026

This Tipifarnib Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Tipifarnib can convert its Small molecule drug profile and FTase biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Tipifarnib (query alias: Tipifarnib)
Modality / target	Small molecule drug; FTase; Ftase inhibitors
Highest global status	Phase 2
Originator	Johnson & Johnson
Active developers	National Cancer Institute, Kura Oncology, Inc.

The MCP disease footprint includes Adrenal Gland Pheochromocytoma, Advanced Malignant Solid Neoplasm, Ependymoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06540963	Phase 2	Recruiting	98	Primary endpoint not disclosed in English source
NCT05693090	Phase 1	Withdrawn	0	Primary endpoint not disclosed in English source
NCT04997902	Phase 1/2	Completed	45	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic Alterations

Phase 2; n=5; evaluation: Not stated in English source. Reported fields: Objective Response Rate (Complete Response + Partial Response) in Pediatric Patients Treated With Tipifarnib = 0 % (90%CI, 0 - 0)

A Phase 2 Study of Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other Myelodysplastic /Myeloproliferative Neoplasias, and Acute Myeloid Leukemia

Phase 2; n=44; evaluation: Not stated in English source. Reported fields: CR = 0 Pts ; CR = 0 Pts

Phase 2 Trial of the Farnesyltransferase Inhibitor Tipifarnib for Relapsed/Refractory Peripheral T Cell Lymphoma

Phase 2; n=65; evaluation: Positive. Reported fields: ORR = 39.7 % (95%CI, 28.1 - 52.5); ORR = 56.3 % (95%CI, 39.3 - 71.8)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Tipifarnib addresses Adrenal Gland Pheochromocytoma, Advanced Malignant Solid Neoplasm, Ependymoma. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 3 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2021-07-06	KURA ONCOLOGY ANNOUNCES CLINICAL COLLABORATION TO EVALUATE TIPIFARNIB IN COMBINATION WITH ALPELISIB IN HEAD AND NECK SQUAMOUS CELL CARCINOMA	Approved	Financial terms not disclosed
2015-03-12	Kura Oncology Announces License Agreement With Janssen Pharmaceutica for Development and Commercialization of Tipifarnib; Closes $60 Million Private Placement and Completes Reverse Merger	Phase 1	Financial terms not disclosed
2014-12-23	Transaction title not available in English source	Phase 1	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Methods of using activin receptor type ii signaling inhibitors”. The milestone feed surfaced a patent-application signal described as “Farnesyltransferase inhibitors for treatment of KRAS-dependent cancers”. The milestone feed surfaced a patent-application signal described as “Novel medicine for treating osteosarcoma”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO